烟草吸烟的治疗:综述
药物联合行为咨询的6个月戒烟率为15.2%,高于短暂建议或常规照护的8.6%。一线治疗应包括药物治疗和行为支持,首选伐尼克兰或联合尼古丁替代疗法。
要点
- 药物联合行为咨询6个月戒烟率15.2%,高于短暂建议或常规照护的8.6%。
- EAGLES试验中伐尼克兰6个月戒烟率21.8%,高于安非他酮16.2%和尼古丁贴片15.7%,均高于安慰剂9.4%。
- 一线治疗应包括药物治疗和行为支持,首选伐尼克兰或联合尼古丁替代疗法。
核心结论
- 一线治疗应包括药物治疗和行为支持,首选伐尼克兰或联合尼古丁替代疗法。
研究设计与样本
- 综述,纳入meta分析和EAGLES随机双盲临床试验等证据。
- meta分析纳入19488名吸烟者;EAGLES试验纳入8144名吸烟者。
主要发现
- 约70%吸烟者想戒烟,戒烟者平均约6次尝试才达长期戒断。
- meta分析中药物联合行为咨询6个月戒烟率15.2%,短暂建议或常规照护为8.6%。
- EAGLES试验6个月戒烟率:伐尼克兰21.8%,安非他酮16.2%,尼古丁贴片15.7%,安慰剂9.4%。
- 尼古丁贴片联合其他尼古丁替代疗法产品比单用更有效;不同机制药物联用(如伐尼克兰联合尼古丁替代疗法)在部分研究中提高戒烟率。
- 简短或强化行为支持可面对面、电话、短信或互联网有效提供。
关键数值与推荐
- 药物联合行为咨询6个月戒烟率15.2%,短暂建议或常规照护8.6%。
- EAGLES试验6个月戒烟率:伐尼克兰21.8%,安非他酮16.2%,尼古丁贴片15.7%,安慰剂9.4%。
临床怎么用
- 临床医生简短戒烟建议加上协助获得戒烟治疗,在几乎所有卫生保健机构常规实施均有效。
- 一线治疗应包括药物治疗和行为支持,首选伐尼克兰或联合尼古丁替代疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: More deaths in the US are attributed to cigarette smoking each year than to any other preventable cause. Approximately 34 million people and an estimated 14% of adults in the US smoke cigarettes. If they stopped smoking, they could reduce their risk of tobacco-related morbidity and mortality and potentially gain up to 10 years of life. OBSERVATIONS: Tobacco smoking is a chronic disorder maintained by physical nicotine dependence and learned behaviors. Approximately 70% of people who smoke cigarettes want to quit smoking. However, individuals who attempt to quit smoking make an average of approximately 6 quit attempts before achieving long-term abstinence. Both behavioral counseling and pharmacotherapy while using nicotine replacement therapy (NRT) products, varenicline, or bupropion are effective treatments when used individually, but they are most effective when combined. In a meta-analysis including 19 488 people who smoked cigarettes, the combination of medication and behavioral counseling was associated with a quit rate of 15.2% over 6 months compared with a quit rate of 8.6% with brief advice or usual care. The EAGLES trial, a randomized double-blind clinical trial of 8144 people who smoked, directly compared the efficacy and safety of varenicline, bupropion, nicotine patch, and placebo and found a significantly higher 6-month quit rate for varenicline (21.8%) than for bupropion (16.2%) and the nicotine patch (15.7%). Each therapy was more effective than placebo (9.4%). Combining a nicotine patch with other NRT products is more effective than use of a single NRT product. Combining drugs with different mechanisms of action, such as varenicline and NRT, has increased quit rates in some studies compared with use of a single product. Brief or intensive behavioral support can be delivered effectively in person or by telephone, text messages, or the internet. The combination of a clinician's brief advice to quit and assistance to obtain tobacco cessation treatment is effective when routinely administered to tobacco users in virtually all health care settings. CONCLUSIONS AND RELEVANCE: Approximately 34 million people in the US smoke cigarettes and could potentially gain up to a decade of life expectancy by stopping smoking. First-line therapy should include both pharmacotherapy and behavioral support, with varenicline or combination NRT as preferred initial interventions.
引用
- Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of Tobacco Smoking: A Review. JAMA. 2022. PMID: 35133411. doi:10.1001/jama.2022.0395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。